A one-day gathering for therapeutic developers, technologists, AI pioneers, and entrepreneurs, together with patients and their advocates, to co-create the future of genetic medicine
We are working to build a world with “genetic agency”: a person’s ability to make informed choices and take action at the DNA level to live a healthier life. It’s a term we’ve started using to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To help make this happen, Dyno is hosting a Genetic Agency Technology Conference (GATC) in Boston on November 11.
The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all — and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone — it requires a community working together with pace to turn powerful emerging technologies into patient impact.
At GATC we’re bringing together leaders from various sectors: therapeutic developers, technologists, AI pioneers, and entrepreneurs along with patients and their advocates. Topics at this meeting will include state of the art gene delivery and AI for sequence design as enabling technologies, and other areas of interest to attendees such as preclinical development, manufacturing and regulatory pathways.
The day will include highly participatory sessions emphasizing connection and conversation. Our assumption is that everyone who attends comes with expertise and a goal.
Empower
Elevate the voices of patients and their advocates as critical experts shaping the next generation of genetic technologies
Connect
Build lasting relationships across the gene therapy ecosystem that are rooted in a shared commitment to advancing genetic agency
Engage
Spark meaningful and candid conversations to challenge norms and bridge the gap between technology innovation and real patient impact
Activate
Gain actionable insights to translate learnings into better treatment options today and goals for future technology development that align with patient priorities
Our exciting lineup of speakers includes:
George Church, PhD
Founding Core Faculty and Synthetic Biology Lead at the Wyss Institute
Sonia Vallabh, PhD
Director of Prion Therapeutic Science at the Broad Institute
Federico Mingozzi, PhD
CEO of Nava Therapeutics and ASGCT Treasurer
Terence Flotte, MD
Provost, Dean, Professor at UMass Chan Medical School and ASGCT President
Victoria Gray
First patient treated with CRISPR gene editing therapy for Sickle Cell Disease
More speakers will be announced soon.
November 11, 2025
8:00 am - 5:00 pm
Conference Programming
5:00 pm - 7:00 pm
Reception and Happy Hour Social
GATC is an invitation-only event, though a limited number of spots are available for those who apply to attend. We welcome anyone interested to submit an application, no later than Oct 10.